close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vor Biopharma

< Previous 1 2 Next >
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today